Breast: The effect of low expression of HER2 on the prognosis of hormone receptor-positive early breast cancer

Estrogen receptor (ER) is positive and human epidermal growth factor receptor 2 (HER2) is negative, which is the most common subtype of early breast cancer

Estrogen receptor (ER) is positive and human epidermal growth factor receptor 2 (HER2) is negative.

We define tumors with negative in situ hybridization (IHC) results of +1 or +2/ISH as "HER2-low"

We define tumors with negative in situ hybridization (IHC) results of +1 or +2/ISH as "HER2-low"

This study aims to investigate whether the expression of HER2 in early, ER-positive, and HER2-negative diseases has an impact on clinicopathological characteristics, and to test the prognostic effect of HER2 expression in the entire population through genomic risk

This time, the research department screened 705 patients , and the final analysis included 608 patients, including 304 HER2-0 patients and 304 HER2-low patients

A total of 705 patients were screened by the research department .

Baseline clinical and pathological characteristics based on HER2 expression status

The median follow-up time was 10.

The median follow-up time was 10.

OS, DFS, and DDFS of the entire study cohort and disaggregated data by genomic risk

The 10-year expected OS rate for HER2-low is 91%, and the 10-year OS rate for HER2-0 disease is 88% (Figure 1A), HR=0.

The 10-year expected OS rate for HER2-low is 91%, and the 10-year OS rate for HER2-0 disease is 88% (Figure 1A), HR=0.

Overall, 497 patients (82%) had a low genomic risk (RS 0-25), including 245 HER2-low patients and 252 HER2-0 patients

Overall, 497 patients (82%) had a low genomic risk (RS 0-25), including 245 HER2-low patients and 252 HER2-0 patients

111 patients had a recurrence score of 26 or above, of which 52 were HER2-0 and 59 were HER2-low

111 patients had a recurrence score of 26 or above, of which 52 were HER2-0 and 59 were HER2-low

Most women with higher genomic risk received adjuvant chemotherapy: 40 (78.

The state of HER2 at the time of disease recurrence is shown in Figure 4
.
There were 68 recurrences, 33 of which were confirmed by biopsy
.
In 10/14 (71%) HER2-0 and 12/19 (63%) HER2-low patients, the HER2 expression on biopsy at the recurrence site was consistent with baseline
.
At recurrence, 4 cases (12%) were HER2 positive by immunohistochemistry (+3) or ISH
.
Immunity and low Oncotype DX score, tend to maintain the original level of HER2 tumors compared to high Oncotype DX score tumors tend to over-express the HER2 receptor at relapse
.

In summary, this study shows that the prognosis of HER2-low is different in the Oncotype DX risk group, and only in patients with high genomic risk, the prognosis of HER2-low tumors is good
.
In the future, it is necessary to conduct larger studies to determine whether HER2-low represents a biomarker that may affect treatment decisions
.

This study shows that the prognosis of HER2-low is different in the Oncotype DX risk group, and only in patients with high genomic risk, the prognosis of HER2-low tumors is good
.
In the future, it is necessary to conduct larger studies to determine whether HER2-low represents a biomarker that may affect treatment decisions
.

 

Original source:

Original source:

Raz Mutai, et al.
Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer.

Raz Mutai, et al.
Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer.
et al .
Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer.

The Breast 60(2021)62-69.
https://doi.
org/10.
1016/j.
breast.
2021.
08.
016

The Breast 60(2021)62-69.
The Breast 60(2021)62-69.




Leave a message here